[{"id":"d6077c21-17bb-4f1e-9fd6-5e8d472b76ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT03854903","created_at":"2021-01-18T19:01:32.210Z","updated_at":"2025-02-25T16:37:21.932Z","phase":"Phase 1","brief_title":"WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor","source_id_and_acronym":"NCT03854903","lead_sponsor":"Georgetown University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant • bosutinib"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 01/09/2025","study_completion_date":" 01/09/2025","last_update_posted":"2025-02-06"},{"id":"fdf62ac7-f79d-46b1-9a07-c4ce7608d067","acronym":"Ascembl","url":"https://clinicaltrials.gov/study/NCT03106779","created_at":"2021-01-17T17:34:34.885Z","updated_at":"2025-02-25T16:36:53.037Z","phase":"Phase 3","brief_title":"Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs","source_id_and_acronym":"NCT03106779 - Ascembl","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 mutation","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bosutinib • Scemblix (asciminib)"],"overall_status":"Completed","enrollment":" Enrollment 233","initiation":"Initiation: 10/26/2017","start_date":" 10/26/2017","primary_txt":" Primary completion: 05/25/2020","primary_completion_date":" 05/25/2020","study_txt":" Completion: 12/04/2024","study_completion_date":" 12/04/2024","last_update_posted":"2025-02-06"},{"id":"613dfa54-e318-471f-a8ed-a12b2572968b","acronym":"CAPTUR","url":"https://clinicaltrials.gov/study/NCT03297606","created_at":"2021-01-18T16:17:30.914Z","updated_at":"2025-02-25T13:52:23.697Z","phase":"Phase 2","brief_title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","source_id_and_acronym":"NCT03297606 - CAPTUR","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Zelboraf (vemurafenib) • sunitinib • Perjeta (pertuzumab) • Cotellic (cobimetinib) • bosutinib • Tukysa (tucatinib) • temsirolimus • axitinib • Erivedge (vismodegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 720","initiation":"Initiation: 03/23/2018","start_date":" 03/23/2018","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-11-12"},{"id":"0e780db3-37b0-4fba-8b2c-04f23ba71bda","acronym":"ASC4FIRST","url":"https://clinicaltrials.gov/study/NCT04971226","created_at":"2021-07-21T12:52:37.177Z","updated_at":"2024-07-02T16:35:06.088Z","phase":"Phase 3","brief_title":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP","source_id_and_acronym":"NCT04971226 - ASC4FIRST","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • nilotinib • bosutinib • Scemblix (asciminib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 404","initiation":"Initiation: 10/06/2021","start_date":" 10/06/2021","primary_txt":" Primary completion: 11/28/2023","primary_completion_date":" 11/28/2023","study_txt":" Completion: 01/18/2028","study_completion_date":" 01/18/2028","last_update_posted":"2024-05-03"},{"id":"0170dcd4-c22d-42e8-a253-3a55399779ea","acronym":"AAML1921","url":"https://clinicaltrials.gov/study/NCT04258943","created_at":"2023-12-14T16:16:46.995Z","updated_at":"2025-02-25T16:25:40.949Z","phase":"Phase 1/2","brief_title":"Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia","source_id_and_acronym":"NCT04258943 - AAML1921","lead_sponsor":"Children's Oncology Group","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bosutinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/06/2020","start_date":" 04/06/2020","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2024-02-22"},{"id":"a976d708-4f7e-45aa-b0eb-eedbc6a94f74","acronym":"TOKIN","url":"https://clinicaltrials.gov/study/NCT04626024","created_at":"2021-01-19T20:35:32.623Z","updated_at":"2024-07-02T16:35:26.331Z","phase":"Phase 2","brief_title":"Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population","source_id_and_acronym":"NCT04626024 - TOKIN","lead_sponsor":"Baylor College of Medicine","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • nilotinib • bosutinib"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/22/2020","start_date":" 12/22/2020","primary_txt":" Primary completion: 11/15/2025","primary_completion_date":" 11/15/2025","study_txt":" Completion: 11/15/2025","study_completion_date":" 11/15/2025","last_update_posted":"2023-12-13"},{"id":"1be42d69-4042-461f-b4f8-dc4841bc042b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03654768","created_at":"2022-04-24T08:59:37.394Z","updated_at":"2024-07-02T16:35:29.499Z","phase":"Phase 2","brief_title":"Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia","source_id_and_acronym":"NCT03654768","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • Jakafi (ruxolitinib) • nilotinib • bosutinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 10/24/2018","start_date":" 10/24/2018","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2023-11-13"},{"id":"9805af40-e9ce-41b8-afa1-e5083a1435ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT02546375","created_at":"2021-01-18T12:19:07.644Z","updated_at":"2024-07-02T16:35:34.983Z","phase":"","brief_title":"A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands","source_id_and_acronym":"NCT02546375","lead_sponsor":"Pfizer","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bosutinib"],"overall_status":"Completed","enrollment":" Enrollment 87","initiation":"Initiation: 07/15/2015","start_date":" 07/15/2015","primary_txt":" Primary completion: 01/16/2017","primary_completion_date":" 01/16/2017","study_txt":" Completion: 01/16/2017","study_completion_date":" 01/16/2017","last_update_posted":"2023-10-03"},{"id":"695c1a45-9603-4f8e-b6ce-75995a62ee90","acronym":"","url":"https://clinicaltrials.gov/study/NCT02311998","created_at":"2021-01-17T18:01:29.030Z","updated_at":"2024-07-02T16:35:42.833Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML","source_id_and_acronym":"NCT02311998","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR • CD22","pipe":"","alterations":" ","tags":["ABL1 • BCR • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bosutinib • Besponsa (inotuzumab ozogamicin)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 04/16/2015","start_date":" 04/16/2015","primary_txt":" Primary completion: 03/23/2022","primary_completion_date":" 03/23/2022","study_txt":" Completion: 03/23/2022","study_completion_date":" 03/23/2022","last_update_posted":"2023-07-17"},{"id":"51b0af63-00ed-4f95-8818-056a9fc2dad9","acronym":"BosuPeg","url":"https://clinicaltrials.gov/study/NCT03831776","created_at":"2022-04-24T08:59:51.579Z","updated_at":"2024-07-02T16:35:50.176Z","phase":"Phase 2","brief_title":"Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis","source_id_and_acronym":"NCT03831776 - BosuPeg","lead_sponsor":"St. Olavs Hospital","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bosutinib"],"overall_status":"Recruiting","enrollment":" Enrollment 212","initiation":"Initiation: 03/25/2019","start_date":" 03/25/2019","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2023-04-19"},{"id":"423e48f4-b2d2-484f-9077-f6c1de7d1e1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02269267","created_at":"2022-04-24T08:56:57.764Z","updated_at":"2024-07-02T16:35:54.161Z","phase":"Phase 2","brief_title":"The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)","source_id_and_acronym":"NCT02269267","lead_sponsor":"Medical College of Wisconsin","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • bosutinib"],"overall_status":"Completed","enrollment":" Enrollment 173","initiation":"Initiation: 12/18/2014","start_date":" 12/18/2014","primary_txt":" Primary completion: 04/06/2021","primary_completion_date":" 04/06/2021","study_txt":" Completion: 04/06/2022","study_completion_date":" 04/06/2022","last_update_posted":"2023-03-03"},{"id":"45f38e29-5e02-4720-be2a-d131cd8e146a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05743465","created_at":"2023-02-24T16:01:24.862Z","updated_at":"2024-07-02T16:35:54.277Z","phase":"","brief_title":"A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia","source_id_and_acronym":"NCT05743465","lead_sponsor":"Takeda","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • Iclusig (ponatinib) • nilotinib • bosutinib"],"overall_status":"Completed","enrollment":" Enrollment 1769","initiation":"Initiation: 10/06/2021","start_date":" 10/06/2021","primary_txt":" Primary completion: 11/30/2022","primary_completion_date":" 11/30/2022","study_txt":" Completion: 11/30/2022","study_completion_date":" 11/30/2022","last_update_posted":"2023-03-02"},{"id":"3803238c-6897-4792-8192-1db65c7b3b43","acronym":"BEST","url":"https://clinicaltrials.gov/study/NCT02810990","created_at":"2021-01-18T13:47:10.028Z","updated_at":"2024-07-02T16:35:56.483Z","phase":"Phase 2","brief_title":"Bosutinib in Elderly Chronic Myeloid Leukemia","source_id_and_acronym":"NCT02810990 - BEST","lead_sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 mutation","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bosutinib"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 11/17/2016","start_date":" 11/17/2016","primary_txt":" Primary completion: 04/30/2020","primary_completion_date":" 04/30/2020","study_txt":" Completion: 06/22/2022","study_completion_date":" 06/22/2022","last_update_posted":"2023-02-03"},{"id":"e6a4679a-3426-425a-a0da-b8e775fb9844","acronym":"","url":"https://clinicaltrials.gov/study/NCT05682924","created_at":"2023-01-12T15:02:34.059Z","updated_at":"2024-07-02T16:35:57.708Z","phase":"","brief_title":"Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib","source_id_and_acronym":"NCT05682924","lead_sponsor":"Samara State Medical University","biomarkers":" VEGFA","pipe":"","alterations":" ","tags":["VEGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bosutinib"],"overall_status":"Recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 05/15/2023","study_completion_date":" 05/15/2023","last_update_posted":"2023-01-12"},{"id":"5bdf9645-0184-444b-9ff7-a2b09bc667bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03885830","created_at":"2022-04-24T08:59:55.328Z","updated_at":"2024-07-02T16:35:57.809Z","phase":"","brief_title":"Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients","source_id_and_acronym":"NCT03885830","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • nilotinib • bosutinib"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 06/20/2019","start_date":" 06/20/2019","primary_txt":" Primary completion: 06/15/2022","primary_completion_date":" 06/15/2022","study_txt":" Completion: 06/15/2022","study_completion_date":" 06/15/2022","last_update_posted":"2023-01-11"},{"id":"1e85ee52-7d64-4842-bb2c-5ba2eab90c67","acronym":"B1871040","url":"https://clinicaltrials.gov/study/NCT01903733","created_at":"2021-08-17T20:53:11.296Z","updated_at":"2024-07-02T16:36:07.142Z","phase":"","brief_title":"Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008","source_id_and_acronym":"NCT01903733 - B1871040","lead_sponsor":"Pfizer","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" ALPL-H","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALPL-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bosutinib"],"overall_status":"Completed","enrollment":" Enrollment 281","initiation":"Initiation: 08/28/2013","start_date":" 08/28/2013","primary_txt":" Primary completion: 06/05/2020","primary_completion_date":" 06/05/2020","study_txt":" Completion: 06/05/2020","study_completion_date":" 06/05/2020","last_update_posted":"2022-07-19"},{"id":"f514e125-fc12-410e-8afb-782e274842a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04655391","created_at":"2021-01-19T20:41:28.630Z","updated_at":"2024-07-02T16:36:09.137Z","phase":"Phase 1b","brief_title":"Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation","source_id_and_acronym":"NCT04655391","lead_sponsor":"City of Hope Medical Center","biomarkers":" FLT3 • ABL1 • BCR • IDH1 • AXL","pipe":" | ","alterations":" IDH1 mutation • BCR-ABL1 fusion • FLT3 mutation • FLT3 D835 • IDH1 R132 • FLT3 I836","tags":["FLT3 • ABL1 • BCR • IDH1 • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • BCR-ABL1 fusion • FLT3 mutation • FLT3 D835 • IDH1 R132 • FLT3 I836"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine • bosutinib • decitabine • Tibsovo (ivosidenib) • Idhifa (enasidenib) • Daurismo (glasdegib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/25/2022","start_date":" 06/25/2022","primary_txt":" Primary completion: 12/15/2023","primary_completion_date":" 12/15/2023","study_txt":" Completion: 12/15/2023","study_completion_date":" 12/15/2023","last_update_posted":"2022-06-09"},{"id":"83369ca2-9ae9-4bda-b69d-55cf1b508d90","acronym":"","url":"https://clinicaltrials.gov/study/NCT03128411","created_at":"2022-04-24T08:58:22.216Z","updated_at":"2024-07-02T16:36:10.164Z","phase":"Phase 2","brief_title":"Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia","source_id_and_acronym":"NCT03128411","lead_sponsor":"Pfizer","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bosutinib"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 05/15/2017","start_date":" 05/15/2017","primary_txt":" Primary completion: 03/12/2019","primary_completion_date":" 03/12/2019","study_txt":" Completion: 03/04/2021","study_completion_date":" 03/04/2021","last_update_posted":"2022-05-19"},{"id":"95eb94a5-51a7-4646-8be1-29e9333f60c4","acronym":"BFORE trial","url":"https://clinicaltrials.gov/study/NCT02130557","created_at":"2021-01-17T17:37:15.836Z","updated_at":"2024-07-02T16:36:30.098Z","phase":"Phase 3","brief_title":"A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia","source_id_and_acronym":"NCT02130557 - BFORE trial","lead_sponsor":"Pfizer","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • bosutinib"],"overall_status":"Completed","enrollment":" Enrollment 536","initiation":"Initiation: 07/15/2014","start_date":" 07/15/2014","primary_txt":" Primary completion: 08/11/2016","primary_completion_date":" 08/11/2016","study_txt":" Completion: 04/17/2020","study_completion_date":" 04/17/2020","last_update_posted":"2021-05-18"},{"id":"bddb89ed-19fe-416c-91b5-bdc13be96180","acronym":"","url":"https://clinicaltrials.gov/study/NCT02638467","created_at":"2021-01-18T12:50:00.864Z","updated_at":"2024-07-02T16:36:39.027Z","phase":"Phase 2","brief_title":"Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy","source_id_and_acronym":"NCT02638467","lead_sponsor":"University of Milano Bicocca","biomarkers":" ABL1 • BCR • HLA-DRB1 • CD34 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["ABL1 • BCR • HLA-DRB1 • CD34 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bosutinib"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 11/29/2018","primary_completion_date":" 11/29/2018","study_txt":" Completion: 02/01/2020","study_completion_date":" 02/01/2020","last_update_posted":"2020-11-05"},{"id":"9ef063d1-0fda-4310-ac44-4f0a58049d17","acronym":"READIT","url":"https://clinicaltrials.gov/study/NCT04578847","created_at":"2022-04-24T09:02:49.111Z","updated_at":"2024-07-02T16:36:40.312Z","phase":"Phase 2","brief_title":"A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)","source_id_and_acronym":"NCT04578847 - READIT","lead_sponsor":"National Research Center for Hematology, Russia","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • nilotinib • bosutinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/15/2020","start_date":" 01/15/2020","primary_txt":" Primary completion: 01/15/2025","primary_completion_date":" 01/15/2025","study_txt":" Completion: 01/15/2025","study_completion_date":" 01/15/2025","last_update_posted":"2020-10-07"},{"id":"ec5762bc-1ad2-4b91-a67d-ae0b4dbb1f6d","acronym":"BOSTRO","url":"https://clinicaltrials.gov/study/NCT02445742","created_at":"2021-01-18T11:43:17.618Z","updated_at":"2024-07-02T16:36:45.500Z","phase":"Phase 2","brief_title":"CML Treated With Bosutinib After Relapse","source_id_and_acronym":"NCT02445742 - BOSTRO","lead_sponsor":"PETHEMA Foundation","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bosutinib"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 06/27/2019","study_completion_date":" 06/27/2019","last_update_posted":"2020-04-29"},{"id":"1cdca0e9-a7f9-4572-a2eb-32d4451abb99","acronym":"BELA","url":"https://clinicaltrials.gov/study/NCT00574873","created_at":"2021-01-18T02:05:58.890Z","updated_at":"2024-07-02T16:37:04.102Z","phase":"Phase 3","brief_title":"Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML","source_id_and_acronym":"NCT00574873 - BELA","lead_sponsor":"Pfizer","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • bosutinib"],"overall_status":"Completed","enrollment":" Enrollment 502","initiation":"Initiation: 02/05/2008","start_date":" 02/05/2008","primary_txt":" Primary completion: 08/31/2010","primary_completion_date":" 08/31/2010","study_txt":" Completion: 05/27/2015","study_completion_date":" 05/27/2015","last_update_posted":"2019-01-08"},{"id":"6ca47a31-d498-4cc9-874d-8cdfd3f7a74f","acronym":"B1871006","url":"https://clinicaltrials.gov/study/NCT00261846","created_at":"2021-01-17T17:25:08.764Z","updated_at":"2024-07-02T16:37:19.471Z","phase":"Phase 2","brief_title":"Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias","source_id_and_acronym":"NCT00261846 - B1871006","lead_sponsor":"Pfizer","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bosutinib"],"overall_status":"Completed","enrollment":" Enrollment 571","initiation":"Initiation: 01/18/2006","start_date":" 01/18/2006","primary_txt":" Primary completion: 09/25/2009","primary_completion_date":" 09/25/2009","study_txt":" Completion: 08/06/2015","study_completion_date":" 08/06/2015","last_update_posted":"2017-07-27"}]